In addition, the YT521-B homology m6A RNA-binding protein-1/enhancer of zeste homolog-2 (YTHDF1/EZH2) axis has been shown to aid in the recruitment of MDSCs through the upregulation of IL-6, another axis to be considered in HCC immunotherapy [198, 199]. The gene discussed is EZH2; the disease is hepatocellular carcinoma.